- Home
- MDCX vs LTRN Comparison
MDCX vs LTRN Comparison
Compare MDCX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- LTRN
- Stock Information
- Founded
- MDCX 2008
- LTRN 2013
- Country
- MDCX Canada
- LTRN United States
- Employees
- MDCX N/A
- LTRN N/A
- Industry
- MDCX
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- MDCX
- LTRN Health Care
- Exchange
- MDCX Nasdaq
- LTRN Nasdaq
- Market Cap
- MDCX 44.0M
- LTRN 36.0M
- IPO Year
- MDCX N/A
- LTRN 2020
- Fundamental
- Price
- MDCX $2.52
- LTRN $3.08
- Analyst Decision
- MDCX Strong Buy
- LTRN Strong Buy
- Analyst Count
- MDCX 2
- LTRN 1
- Target Price
- MDCX $23.50
- LTRN $25.00
- AVG Volume (30 Days)
- MDCX 423.8K
- LTRN 60.7K
- Earning Date
- MDCX 05-12-2025
- LTRN 08-07-2025
- Dividend Yield
- MDCX N/A
- LTRN N/A
- EPS Growth
- MDCX N/A
- LTRN N/A
- EPS
- MDCX N/A
- LTRN N/A
- Revenue
- MDCX N/A
- LTRN N/A
- Revenue This Year
- MDCX N/A
- LTRN N/A
- Revenue Next Year
- MDCX N/A
- LTRN N/A
- P/E Ratio
- MDCX N/A
- LTRN N/A
- Revenue Growth
- MDCX N/A
- LTRN N/A
- 52 Week Low
- MDCX $1.80
- LTRN $2.55
- 52 Week High
- MDCX $8.94
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- LTRN 44.79
- Support Level
- MDCX N/A
- LTRN $3.09
- Resistance Level
- MDCX N/A
- LTRN $3.33
- Average True Range (ATR)
- MDCX 0.00
- LTRN 0.17
- MACD
- MDCX 0.00
- LTRN 0.00
- Stochastic Oscillator
- MDCX 0.00
- LTRN 22.19
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.